© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Michael R. DeBaun, MD, MPH, reviews the use of recent FDA-approved therapies along with the conventional treatment options for the management of sickle cell disease.
May 24th 2021
Michael R. DeBaun, MD, MPH, reviews the NHLBI (National Heart, Lung & Blood Institute) recommendations for screening and monitoring of anemia-related disease manifestations and the goals of therapy for patients with sickle cell disease (SCD).
A review of the phase 3 HOPE trial evaluating the use of oral, once-daily HbS polymerization inhibitor, voxelotor, for the treatment of sickle cell disease.
June 1st 2021
Michael R. DeBaun, MD, MPH, reviews the use of crizanlizumab and its effect on vaso-occlusive crises and opioid use for pain management in patients with sickle cell disease as seen in the SUSTAIN trial.
Assessing the role of voxelotor and crizanlizumab as agents for the management of sickle cell disease and the importance of shared-decision making between providers, patients, and caregivers.
June 7th 2021
Considerations for using HSCT (hematopoietic stem cell transplantation) in patients with sickle cell disease.
Michael R. DeBaun, MD, MPH, provides insight on the screening and monitoring procedure for red blood cell transfusion for the management of sickle cell disease.
June 14th 2021
An expert in hematology/oncology discusses the emerging role of gene therapy to treat sickle cell disease.
June 21st 2021
Strategies to avoid complications of sickle cell disease and ensure non-dependency on opioids when treating patients for pain as a result of the disease.